Results 161 to 170 of about 21,108 (240)

Glucagon‐Like Peptide‐1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No Diabetes

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
Among obese, non‐diabetic patients with HFpEF, GLP‐1 RA therapy was not significantly associated with incident atrial fibrillation but was associated with lower all‐cause mortality. Prospective studies are needed to clarify the potential role of GLP‐1 RAs in AF prevention. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) reduce
Farah Rassam, Esteban Kosak Lopez, Sarah Sass, Thitiphan Srikulmontri, Evan Isaacs, John Malin, Phuuwadith Wattanachayakul, Olayinka Afolabi‐Brown   +7 more
wiley   +1 more source

Cardiovascular–Kidney–Metabolic Overlaps, Clinical Outcomes, and Medications Among Patients With Heart Failure: Results From the Chinese Cardiovascular Association Database–Heart Failure Center Registry

MedComm, Volume 7, Issue 10, October 2026.
In a nationwide heart failure cohort, cardiovascular–kidney–metabolic (CKM) multimorbidity was common in Chinese hospitalized heart failure (HF) patients and associated with poor prognosis. Higher CKM burden and combinations identified high‐risk patients.
Xiang Wang, Jingkuo Li, Yi Li, Lubi Lei, Wei Wang, Xuyang Meng, Chenxi Xia, Chenguang Yang, Lihua Zhang, Yuhua Liao, Weimin Li, Yugang Dong, Xinli Li, Jingmin Zhou, Jiefu Yang, Fang Wang   +15 more
wiley   +1 more source

Prospective Evaluation of Quality-of-Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION-HF 12-Month Results. [PDF]

Clin Cardiol
Potoupni V, Boulmpou A, Maragkoudakis S, Briasoulis A, Foukarakis E, Stavrati A, Papadopoulos K, Naka KK, Kotsia A, Parissis I, Ziakas A, Adamopoulos S, Tziakas D, Patsilinakos S, Konstantinidou M, Davlouros P, Christogiannis Z, Tsitlakidis K, Pantelakis I, Stefanakis G, Kolios M, Baltogiannis I, Voltyrakis E, Varounis C, Samothrakitis A, Krikidis D, Tsialoukis P, Paparepa Z, Gourlis D, Papoutsidakis N, Karavidas A, Papadopoulos C.   +31 more
europepmc   +1 more source

5G Cloud‐Enabled Telemedicine for Remote Management of Heart Failure Patients With Implantable Cardioverter‐Defibrillators: A Multicenter Open‐Label Randomized Controlled Trial

MedComm, Volume 7, Issue 10, October 2026.
Postoperative follow‐up for patients with implantable cardioverter‐defibrillators and cardiac resynchronization therapy defibrillators (ICD/CRT‐D) is often delayed in remote areas because of geographic barriers and limited healthcare resources, increasing the risk of adverse outcomes. The “Make Changes” study, was a prospective, multicenter, open‐label
Pan Li, Fayuan Fu, Yiding Qi, Xianxian Zhao, Yingyi Qin, Xinghua Shan, Jing Jiang, Guowei Wang, Jingjuan Huang, Bo Liu, Zhifu Guo, Zhongkai Wang   +11 more
wiley   +1 more source

<i>GSK3B</i> variations influence renoprotective responses to dapagliflozin in diabetic kidney disease. [PDF]

iScience
Song J, Xu Y, Zhuang Y, Yang T, Chen Y, Ying C, Lu Q, Wang T, Yin X.   +8 more
europepmc   +1 more source

Mitochondrial Fusion and Fission in Age‐Related Cardio‐Cerebral Diseases: Mechanisms and Interventions

Aging Cell, Volume 25, Issue 10, October 2026.
Mitochondrial fission‐fusion imbalance contributes to age‐related cardio‐cerebral diseases like Alzheimer's disease, Parkinson's disease, Cerebral Infarction, Arteriosclerosis, Myocardial Infarction, Cardiac valve disease, Hypertension, and Cardiomyopathy. This review summarizes its regulatory mechanisms and interventions.
Yuyao Yin, Zijian Li
wiley   +1 more source

Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis. [PDF]

Calcif Tissue Int
Pelepenko LE, Barreto J, Martins MP, Chiteculo PB, Camargo JM, de Oliveira MC, Corrêa EA, Pascoa M, Guerra-Junior G, Dominguez WV, Carbonara CEM, Louvet L, Moyses RMA, Kuro-O M, Sposito AC, de Oliveira RB.   +15 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, Volume 154, Issue 4, Page 305-312, October 2026.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source

Euglycemic ketoacidosis in a nondiabetic patient receiving dapagliflozin for heart failure. [PDF]

JCEM Case Rep
Silveira G, Kvasha Y, Shah P, Shah H, Gogineni J.   +4 more
europepmc   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source